本期信息
截至2026年6月30日止六个月，亿胜生物科技录得营收7.85亿港元，同比减少10.5%。经调整净利润为1.11亿港元，同比下降32.2%。报告期内，毛利约为6.56亿港元，毛利率约83.66%，较上年同期下降5.12个百分点。
在费用方面，分销及销售开支约3.97亿港元，同比下降约15.9%，占营收比例由去年同期的约53.80%下降至本期的约50.54%。行政开支增至约1.27亿港元，在营收中的占比约16.17%，同比有所上升。研发投入在本期费用化金额约2,580万港元，较去年同期增加约19%，占营收约3.29%。
期内经营活动产生的现金净额约0.99亿港元，较上年同期减少约19.4%。
业务分项
按分部划分，眼科业务录得营收3.67亿港元，同比下降12.0%；外科业务营收3.41亿港元，同比下滑24.0%；医疗保健及伙伴服务营收7,630万港元，较上年同期增长约646.5%。公司表示，眼科和外科板块的销售下滑主要与本期增值税政策及监管政策趋严相关，而医疗保健及伙伴服务呈现出快速增长，拉动整体业绩结构的多元化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.